ADC Therapeutics (NYSE:ADCT) is one of the best long term penny stocks with huge upside potential. On October 16, H.C. Wainwright analyst Robert Burns lowered the price target on ADC Therapeutics to $7 from $8 and maintained a Buy rating on the shares. The firm reduced the price target after factoring in the private placement financing. H.C. Wainwright Lowers ADC Therapeutics (ADCT) PT to $7 Following $60M Private Placement In other news, earlier on October 12, DC Therapeutics announced a $60 million pri ...